Newron Pharmaceuticals SpA (NWPHF) Ratios
Newron Pharmaceuticals SpA Ratios
NWPHF's free cash flow for Q2 2026 was $-10.73M. For the 2026 fiscal year, NWPHF's free cash flow was decreased by $-20.90K and operating cash flow was $-10.71M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.76 | 2.60 | 0.68 | 5.65 | 10.79 |
| Quick Ratio | 0.76 | 2.60 | 0.68 | 5.65 | 10.79 |
| Cash Ratio | 0.24 | 0.29 | 0.22 | 2.66 | 6.85 |
| Solvency Ratio | -0.26 | 0.26 | -0.29 | -0.34 | -0.31 |
| Operating Cash Flow Ratio | 0.65 | -0.75 | -0.35 | -2.20 | -3.13 |
| Short-Term Operating Cash Flow Coverage | 0.87 | -1.31 | -0.46 | 0.00 | 0.00 |
| Net Current Asset Value | $ -13.10M | $ -1.35M | $ -36.12M | $ -22.73M | $ -7.95M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.95 | 0.79 | 1.87 | 1.23 | 0.85 |
| Debt-to-Equity Ratio | -3.43 | 34.62 | -1.62 | -3.25 | 13.87 |
| Debt-to-Capital Ratio | 1.41 | 0.97 | 2.62 | 1.44 | 0.93 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.96 | -6.20 | 1.45 | 0.93 |
| Financial Leverage Ratio | -3.60 | 43.83 | -0.86 | -2.65 | 16.25 |
| Debt Service Coverage Ratio | -0.13 | 1.15 | -0.45 | -3.06 | -4.09 |
| Interest Coverage Ratio | -1.06 | 6.01 | -2.79 | -3.05 | -4.23 |
| Debt to Market Cap | 0.07 | 0.28 | 0.51 | 1.62 | 1.53 |
| Interest Debt Per Share | 2.13 | 2.95 | 2.95 | 2.80 | 2.58 |
| Net Debt to EBITDA | -5.70 | 1.68 | -3.56 | -2.42 | -1.52 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -24.72% | 50.10% | -132.85% | -221.94% | -207.67% |
| EBITDA Margin | -23.81% | 50.47% | -130.63% | -218.62% | -206.86% |
| Operating Profit Margin | -24.56% | 50.93% | -128.40% | -218.28% | -214.46% |
| Pretax Profit Margin | -64.59% | 41.63% | -178.87% | -286.71% | -258.31% |
| Net Profit Margin | -69.22% | 30.83% | -179.13% | -287.05% | -258.61% |
| Continuous Operations Profit Margin | -69.22% | 30.83% | -179.13% | -287.05% | -258.61% |
| Net Income Per EBT | 107.16% | 74.05% | 100.15% | 100.12% | 100.11% |
| EBT Per EBIT | 263.02% | 81.74% | 139.31% | 131.35% | 120.45% |
| Return on Assets (ROA) | -33.08% | 24.79% | -62.72% | -47.03% | -29.52% |
| Return on Equity (ROE) | 118.99% | 1086.63% | 54.25% | 124.68% | -479.59% |
| Return on Capital Employed (ROCE) | 46.65% | 64.78% | 380.03% | -41.37% | -26.39% |
| Return on Invested Capital (ROIC) | -17.02% | 35.92% | -59.97% | -41.15% | -26.30% |
| Return on Tangible Assets | -33.08% | 24.79% | -62.72% | -47.03% | -29.52% |
| Earnings Yield | -2.59% | 8.96% | -17.06% | -62.62% | -53.50% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.11 | 1.21 | 3.58 | 3.13 | 4.41 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 26.01 | 61.62 | 22.36 | 11.56 | 9.99 |
| Asset Turnover | 0.48 | 0.80 | 0.35 | 0.16 | 0.11 |
| Working Capital Turnover Ratio | 1.50 | 3.63 | 1.28 | 0.21 | 0.17 |
| Cash Conversion Cycle | 117.48 | 301.31 | 101.96 | 116.44 | 82.86 |
| Days of Sales Outstanding | 117.48 | 301.31 | 101.96 | 116.44 | 82.86 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 117.48 | 301.31 | 101.96 | 116.44 | 82.86 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.63 | -0.95 | -0.57 | -0.62 | -0.64 |
| Free Cash Flow Per Share | 1.63 | -0.95 | -0.57 | -0.62 | -0.64 |
| Dividend Paid and CapEx Coverage Ratio | 688.35 | -1354.92 | -921.82 | -616.22 | -572.25 |
| Capital Expenditure Coverage Ratio | 688.35 | -1354.92 | -921.82 | -616.22 | -572.25 |
| Operating Cash Flow Coverage Ratio | 0.85 | -0.35 | -0.21 | -0.24 | -0.27 |
| Operating Cash Flow to Sales Ratio | 1.70 | -0.34 | -1.12 | -1.82 | -1.99 |
| Free Cash Flow Yield | 6.36% | -9.97% | -10.67% | -39.77% | -41.16% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -38.23 | 11.20 | -5.86 | -1.60 | -1.87 |
| Price-to-Sales (P/S) Ratio | 26.73 | 3.44 | 10.50 | 4.58 | 4.83 |
| Price-to-Book (P/B) Ratio | -45.95 | 121.21 | -3.18 | -1.99 | 8.96 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 15.73 | -10.03 | -9.37 | -2.51 | -2.43 |
| Price-to-Operating Cash Flow Ratio | 15.70 | -10.03 | -9.38 | -2.52 | -2.43 |
| Price-to-Earnings Growth (PEG) Ratio | 0.21 | -0.06 | 0.82 | -0.10 | 0.06 |
| Enterprise Value Multiple | -117.96 | 8.49 | -11.59 | -4.52 | -3.85 |
| Enterprise Value | 537.26M | 220.26M | 137.18M | 60.17M | 45.92M |
| EV to EBITDA | -117.96 | 8.49 | -11.59 | -4.52 | -3.85 |
| EV to Sales | 28.09 | 4.29 | 15.15 | 9.87 | 7.97 |
| EV to Free Cash Flow | 16.52 | -12.50 | -13.51 | -5.42 | -4.00 |
| EV to Operating Cash Flow | 16.50 | -12.50 | -13.53 | -5.42 | -4.01 |
| Tangible Book Value Per Share | -0.56 | 0.08 | -1.68 | -0.79 | 0.17 |
| Shareholders’ Equity Per Share | -0.56 | 0.08 | -1.68 | -0.79 | 0.17 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.07 | 0.26 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.96 | 2.77 | 0.51 | 0.34 | 0.32 |
| Net Income Per Share | -0.66 | 0.85 | -0.91 | -0.98 | -0.84 |
| Tax Burden | 1.07 | 0.74 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 2.61 | 0.83 | 1.35 | 1.29 | 1.24 |
| Research & Development to Revenue | 0.79 | 0.27 | 1.45 | 1.98 | 1.87 |
| SG&A to Revenue | 0.25 | 0.15 | 0.44 | 0.58 | 0.61 |
| Stock-Based Compensation to Revenue | 0.01 | 0.00 | 0.02 | 0.08 | 0.13 |
| Income Quality | -2.64 | -0.82 | 0.63 | 0.63 | 0.77 |
Currency in EUR